Get the Stockscreener App
78.53
7.58%
5.53
After Hours:
78.82
0.29
+0.37%
Apogee Therapeutics Inc stock is traded at $78.53, with a volume of 3.53M.
It is up +7.58% in the last 24 hours and up +10.78% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$73.00
Open:
$74.59
24h Volume:
3.53M
Relative Volume:
3.29
Market Cap:
$5.41B
Revenue:
-
Net Income/Loss:
$-255.84M
P/E Ratio:
-18.63
EPS:
-4.2149
Net Cash Flow:
$-232.60M
1W Performance:
+17.61%
1M Performance:
+10.78%
6M Performance:
+109.30%
1Y Performance:
+96.87%
1-Day Range:
$73.98
$85.04
1-Week Range:
$65.22
$85.04
52-Week Range:
$26.20
$85.04
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.53 | 5.03B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics announces $377.4 million public offering of common stock - Investing.com
Apogee Therapeutics Prices Upsized Public Equity Offering - TipRanks
Apogee Therapeutics Prices 5.75 Million-Share Offering at $70, Expecting $377.4 Million Net - TradingView
Apogee Therapeutics (NASDAQ: APGE) raises $329M in 5M-share offering - Stock Titan
[8-K] Apogee Therapeutics, Inc. Reports Mate... - Stock Titan
Jane Henderson sells 6,000 APGE restricted shares (NASDAQ: APGE) - Stock Titan
Apogee Therapeutics stock hits all-time high at 84.56 USD By Investing.com - Investing.com India
Apogee Therapeutics (NASDAQ:APGE) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
Latest APGE NewsApogee Therapeutics Appoints Mark C. McKenn... - Stock Titan
Biotech Apogee sells 5 million shares at $70 to raise $350M - Stock Titan
Rally Mode: Is Apogee Therapeutics Inc attractive for institutional investors2026 Sector Moves & AI Driven Price Forecasts - baoquankhu1.vn
Apogee Therapeutics announces $300 million public offering - MSN
Apogee Therapeutics prices $350 million stock offering at $70 By Investing.com - Investing.com South Africa
Apogee Therapeutics Prices $350 Million Share Offering - marketscreener.com
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Bitget
Apogee Therapeutics prices $350 million stock offering at $70 - Investing.com
Apogee Therapeutics, Inc. Prices Public Offering of 5 Million Shares at $70.00 Per Share, Anticipating $350 Million in Gross Proceeds - Quiver Quantitative
Apogee Therapeutics prices $350 million underwritten public offering at $70.00 per share - marketscreener.com
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - GlobeNewswire Inc.
Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart DataHas The Bull Case Changed? - Sahm
Apogee Therapeutics (NASDAQ:APGE) Trading Down 6.5%What's Next? - MarketBeat
Apogee Therapeutics, Insmed, Sunoco - TradingView
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone (APGE) - Seeking Alpha
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $125.00 - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $130.00 - MarketBeat
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - TradingView
A Quick Look at Today's Ratings for Apogee Therapeutics(APGE.US), With a Forecast Between $100 to $160 - Moomoo
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $160.00 at Guggenheim - MarketBeat
Apogee Therapeutics stock price target raised to $160 by Guggenheim on trial data - Investing.com
Apogee Therapeutics launches $300 million stock offering By Investing.com - Investing.com India
Apogee progressing zumilokibart on positive Phase II data - The Pharma Letter
Apogee makes long-interval dosing case in atopic dermatitis, Valneva falls on Lyme disease data, and more - BioCentury
Apogee Therapeutics Gains Momentum Amid Phase 2 Study Success - timothysykes.com
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Bitget
Mizuho reiterates Apogee Therapeutics stock rating on AD trial data By Investing.com - Investing.com South Africa
Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE) - Seeking Alpha
Small Biotech Zips Higher On Its Regeneron-Rivaling Test Results - Investor's Business Daily
Apogee Therapeutics, Inc. announces proposed $300 million underwritten public offering - marketscreener.com
Apogee Therapeutics (NASDAQ: APGE) seeks $300M in registered share offering - Stock Titan
Apogee Therapeutics launches $300 million stock offering - Investing.com
Apogee seeks $300M to fund clinical trials and manufacturing - Stock Titan
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-03-23 - Seeking Alpha
Crude Oil Falls Sharply; Dell Shares Spike Higher - Benzinga
APGE Stock On The Rise as Analyst Upgrades Predict Growth - StocksToTrade
Apogee Therapeutics Reports Positive 52-Week Phase 2 Results for Zumilokibart in Atopic Dermatitis With Durable Efficacy and Infrequent Dosing 13 - Minichart
BofA raises Apogee Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Apogee Therapeutics stock holds at Hold as trial data beats views By Investing.com - Investing.com Australia
Promising Biotech Stocks To ConsiderMarch 23rd - MarketBeat
Understanding the Setup: (APGE) and Scalable Risk - Stock Traders Daily
Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress - StocksToTrade
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):